Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?
Although Inovio's (NASDAQ: INO) shares lost half of their value in a little over a month this summer, shareholders have since given the biotech company a glimmer of hope. The stock soared 20% in one trading session this week on optimism that details from Inovio's coronavirus vaccine trials will soon be revealed and that extra funding could follow. Inovio began to fall out of favor with investors in late June when it reported interim results from its phase 1 study, from which investors had expected more detailed data than they got.
